Table of contents
July 2007 Vol 7 No 7
From the editors
p487 | doi:10.1038/nrc2188
Research Highlights
MicroRNA: Another piece in the p53 puzzle | PDF (98 KB)
p488 | doi:10.1038/nrc2178
DNA repair: The big and the small picture | PDF (197 KB)
p489 | doi:10.1038/nrc2176
In the news
Vitamin D gets an A+ | PDF (66 KB)
p489 | doi:10.1038/nrc2187
Tumour supressor: Surviving the tumour suppressor | PDF (126 KB)
p490 | doi:10.1038/nrc2179
Cancer stem cells: Fishing for clues | PDF (190 KB)
p490 | doi:10.1038/nrc2181
Chemotherapeutics: Lethal and resistant partners | PDF (105 KB)
p491 | doi:10.1038/nrc2183
Leukaemia: Reduction increases risk | PDF (118 KB)
p492 | doi:10.1038/nrc2182
In brief
Tumour suppressors | Nuclear receptors | Signalling | PDF (84 KB)
p492 | doi:10.1038/nrc2184
Genomics: Finding needles in a haystack | PDF (225 KB)
p493 | doi:10.1038/nrc2177
In brief
Tumour suppressors | Angiogenesis | Metastasis | PDF (84 KB)
p493 | doi:10.1038/nrc2185
Endometrial cancer: Another tyrosine kinase target? | PDF (117 KB)
p494 | doi:10.1038/nrc2180
Trial Watch
Folic acid and colorectal cancer risk | PDF (73 KB)
p494 | doi:10.1038/nrc2186
Reviews
CDC25 phosphatases in cancer cells: key players? Good targets?
Rose Boutros, Valérie Lobjois & Bernard Ducommun
p495 | doi:10.1038/nrc2169
Cell division cycle 25 (CDC25) phosphatases regulate key cell-cycle transitions. Thus, it is not surprising that CDC25 overexpression has been reported in a significant number of human cancers. What are the roles of CDC25 phosphatases in abnormal cell proliferation, and what is the future for targeting CDC25 activity in cancer treatment?
Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development
Gary J. Kelloff & Caroline C. Sigman
p508 | doi:10.1038/nrc2154
Can the process of new cancer-preventive drug development be improved by focusing on precancer (intraepithelial neoplasia) to better identify subjects at risk and prove efficacy in shorter, smaller trials?
Calcium and cancer: targeting Ca2+ transport
Gregory R. Monteith, Damara McAndrew, Helen M. Faddy & Sarah J. Roberts-Thomson
p519 | doi:10.1038/nrc2171
Altered expression of specific Ca2+ channels and pumps are characterizing features of some cancers. The ability of Ca2+ to regulate both cell death and proliferation, combined with the potential for pharmacological modulation, offers the opportunity for a set of new drug targets in cancer. Which Ca2+ channels and pumps should be targeted and what strategy should be used?
Gene methylation and early detection of genitourinary cancer: the road ahead
Paul Cairns
p531 | doi:10.1038/nrc2170
Inactivation of cancer-relevant genes through DNA methylation is a common event in tumours, including genitourinary cancers. The clinical implementation of gene methylation screenings could provide a new avenue for the early detection of genitourinary cancers, which are increasing worldwide. What are the current challenges?
Perspectives
Opinion
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Christos Sotiriou & Martine J. Piccart
p545 | doi:10.1038/nrc2173
The advent of microarray technology has led to a flurry of gene-expression profiling studies aimed at defining patients into more clinically-relevant groups at the same time as gaining new insights into cancer pathology. This is particularly evident for breast cancer research. What are the current limitations and future prospects for the translation of molecular signatures?
Opinion
Targeting the protein kinase C family: are we there yet?
Helen J. Mackay & Christopher J. Twelves
p554 | doi:10.1038/nrc2168
The protein kinase C family of serine/threonine kinases is implicated in tumorigenesis. Although targeting these kinases for cancer therapy is not a new idea, the results from clincal trials with several agents have been disapointing. Why is this?
Correspondence
Correspondence: Paleopathology of malignant tumours supports the concept of human vulnerability to cancer
Andreas G. Nerlich & Beatrice E. Bachmeier
p563 | doi:10.1038/nrc2071-c1
Erratum: Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert, Kevin Shannon & Gideon Bollag
| doi:10.1038/nrc2175
